Would you consider using a PARP inhibitor as maintenance therapy after initial platinum chemotherapy in a patient with metastatic pancreatic cancer who has a somatic non-BRCA DNA damage repair gene alteration?

This is an important question regarding the use of a PARPi as maintenance therapy in HRD genes beyond BRCA1/2, including, PALB2, FANC, CHEK, ATM, NBN, RAD51, MRE11, BARD, etc. As of now, there are limited data to confirm value, however, this is the subject of several ongoing trials evaluating the ro...